Drug Profile
Research programme: CNS disorders therapies - (now Teva Pharmaceutical Industries)/Transition Therapeutics
Latest Information Update: 27 Oct 2011
Price :
$50
*
At a glance
- Originator Cephalon; Transition Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 14 Apr 2010 Discontinued - Preclinical for CNS disorders in USA (unspecified route)
- 07 Nov 2005 Protana has been acquired and merged into Transition Therapeutics
- 18 Aug 2004 MDS Proteomics is now called Protana